CJC-1295 with Drug Affinity Complex (DAC) is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH) incorporating a maleimidoproprionic acid-lysine modification at position 30 — the Drug Affinity Complex — which enables covalent binding to the cysteine-34 residue of serum albumin in vivo. Molecular weight 3647.08 g/mol. This albumin-binding modification is the defining pharmacokinetic feature that distinguishes it from CJC-1295 without DAC.
By binding covalently to circulating albumin, CJC-1295 DAC achieves a substantially extended plasma half-life relative to native GHRH or its unmodified analogs. Endogenous GHRH has a plasma half-life of only a few minutes due to DPP-IV cleavage; the DAC modification protects against enzymatic degradation while albumin binding provides a slow-release reservoir effect. This pharmacokinetic profile makes CJC-1295 DAC a valuable research tool for studying the effects of prolonged, sustained GHRH receptor engagement versus the pulsatile stimulation characteristic of endogenous GHRH and shorter-acting analogs such as Sermorelin or CJC-1295 without DAC.
Research applications include investigations of pituitary somatotroph biology under sustained GHRH receptor activation, comparative pharmacokinetic modeling, GH axis desensitization studies, and albumin as a pharmacokinetic platform for peptide drug delivery research. It is frequently used alongside Ipamorelin in GH axis research as the two compounds act via distinct, complementary receptor mechanisms — GHRH receptor and GHS-R1a respectively.
Supplied as a lyophilized powder. Each lot is independently tested by HPLC-UV at 218nm with a minimum purity threshold of ≥99.3%. Molecular identity confirmed by LC-MS prior to release. Certificate of Analysis available for every lot number.
For laboratory and in-vitro research use only. Not for human or veterinary use. Not FDA approved.
